These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17577792)

  • 1. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
    Ross DM; Jackson SR; Browett PJ
    Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
    [No Abstract]   [Full Text] [Related]  

  • 2. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
    Fava C; Cortes J
    Am J Hematol; 2008 Sep; 83(9):755. PubMed ID: 18615551
    [No Abstract]   [Full Text] [Related]  

  • 3. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
    Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib mesylate in chronic myeloid leukemia.
    Carella AM; Lerma E
    Curr Stem Cell Res Ther; 2007 Sep; 2(3):249-51. PubMed ID: 18220908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib.
    Ugurel S; Lahaye T; Hildenbrand R; Glorer E; Reiter A; Hochhaus A; Schadendorf D; Goerdt S
    Br J Dermatol; 2003 Sep; 149(3):678-9. PubMed ID: 14511021
    [No Abstract]   [Full Text] [Related]  

  • 6. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
    Chee YL; Vickers MA; Stevenson D; Holyoake TL; Culligan DJ
    Leukemia; 2003 Mar; 17(3):634-5. PubMed ID: 12646955
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
    Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
    [No Abstract]   [Full Text] [Related]  

  • 9. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
    Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
    Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
    Georgalas I; Pavesio C; Ezra E
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1585-6. PubMed ID: 17562067
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
    Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
    Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 16. Cocaine abuse may influence the response to imatinib in CML patients.
    Breccia M; Gentilini F; Alimena G
    Haematologica; 2007 Mar; 92(3):e41-2. PubMed ID: 17405756
    [No Abstract]   [Full Text] [Related]  

  • 17. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D; Lipton J
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First case of immune-mediated haemolytic anaemia associated to imatinib mesylate.
    Novaretti MC; Fonseca GH; Conchon M; Dorlhiac-Llacer PE; Chamone Dde A
    Eur J Haematol; 2003 Dec; 71(6):455-8. PubMed ID: 14703696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
    Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.